You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

 

Online download statistics by month:

Online download statistics by month: April 2021 to July 2025

AbstractFullPdf
Apr 2021465464201
May 202146546565
Jun 202125225252
Jul 202114514535
Aug 202110210238
Sep 2021828225
Oct 2021757530
Nov 2021969727
Dec 2021999955
Jan 20229810251
Feb 2022797945
Mar 2022919134
Apr 2022939438
May 202210710861
Jun 2022768035
Jul 2022586435
Aug 2022818328
Sep 2022767621
Oct 2022626334
Nov 2022575940
Dec 2022373716
Jan 2023383819
Feb 2023798427
Mar 2023636525
Apr 2023383823
May 2023242424
Jun 2023303117
Jul 2023303126
Aug 2023272712
Sep 2023292915
Oct 2023394018
Nov 2023686836
Dec 202312012034
Jan 2024444520
Feb 2024424534
Mar 2024353654
Apr 2024434433
May 202414114641
Jun 2024575926
Jul 202425525738
Aug 2024363620
Sep 2024525129
Oct 2024606242
Nov 2024737427
Dec 2024646532
Jan 2025515217
Feb 2025565726
Mar 2025484834
Apr 2025868741
May 2025394134
Jun 2025535315
Jul 2025110
Total451745711805